Psyence Biomed Australian Subsidiary, Psyence Australia Partners With Fluence And iNGENū CRO To Train Research Therapists For Phase IIb Psilocybin Trial
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomed's Australian subsidiary, Psyence Australia, has partnered with Fluence and iNGENū CRO to train research therapists for a Phase IIb psilocybin trial. This collaboration aims to advance the study and potential therapeutic applications of psilocybin.
April 08, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Psyence Biomed's partnership for a Phase IIb psilocybin trial could enhance its position in the psychedelic therapy market.
The partnership for the Phase IIb trial is likely to be viewed positively by investors, as it demonstrates Psyence Biomed's commitment to advancing psychedelic therapy research. This could potentially lead to breakthroughs in treatment options, enhancing PBM's market position and investor interest.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90